Article ID Journal Published Year Pages File Type
2137886 Leukemia Research 2009 7 Pages PDF
Abstract

Compound 48 (C48) is a novel dual ligand for peroxisome proliferator-activated receptor α and γ (PPARα/γ). Culture of imatinib-sensitive and -resistant CML cell lines with C48 resulted in a strong growth inhibition which associated with G0/G1 cell cycle arrest. However, it showed no obvious toxicity to normal CD34+ hematopoietic stem cells. Decrease of pSTATs and pAKT were noticed suggesting that interference of AKT and STATs signaling may be the mechanisms for the effects of PPARα/γ ligands. Of more clinical importance, this ligand strongly enhanced the anticancer-effects of imatinib. Overall, our data suggest that the PPARα/γ ligands may have potentials in the treatment of CML in an adjuvant setting either before or after the development of imatinib resistance.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Authors
, , , , , , ,